{"entity":{"id":"nct02762266","kind":"trial","name":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","aka":[],"tldr":"A phase 3 trial of Ethiodized oil in Hepatocellular carcinoma, run by Stanford University, recorded as terminated on the registry.","summary":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization is a phase 3 interventional study registered as NCT02762266 by Stanford University, with 13 participants recorded, started 2016-02-27 and due to reach its primary completion in 2022-12-31. Interventions recorded: Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent, lipiodol. Conditions recorded: Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma.\n\nLinked to the drug Ethiodized oil because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02762266","url":"https://clinicaltrials.gov/study/NCT02762266"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc","hcc-intermediate"],"sections":[],"technologies":[],"targets":[],"drugs":["ethiodized-oil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02762266","phase":"3","setting":"International Randomized Study of Transarterial Chemoembolization (TACE) Versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma After Initial TACE","sponsor":"Stanford University","started":"2016-02-27","startedType":"actual","yearReported":2024,"enrolled":13,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of Participants With a Local Progression Event","primary":true,"unit":"participants","arms":[{"name":"Transarterial Chemoembolization (TACE)","n":4,"value":0,"note":"Figures from the ClinicalTrials.gov results section (first posted 2024-03-12), not from a publication"},{"name":"Stereotactic Body Radiation Therapy (SBRT)","n":6,"value":0}],"source":"https://clinicaltrials.gov/study/NCT02762266?tab=results"}]},"route":"/trials/nct02762266/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/"}],"drug":[{"id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/"}]}}